A Phase 2/3 interventional study of Fx-1006A and Placebo in Familial Amyloid Polyneuropathy, sponsored by Pfizer. Completed at 10 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-12-17.
Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Amyloid Neuropathies, Familial with a site in Portugal — 4 open to participants now, 5 under way, 2 of them phase 3. Amyloid Neuropathies, Familial · Portugal.
Among the 13 studies in Amyloid Neuropathies, Familial with a site in Portugal, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2007, is one of 3 in phase 2/3, and was the 1st registered.
188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.
Browse Amyloid Neuropathies, Familial studies →4 of the 13 studies in Amyloid Neuropathies, Familial with a site in Portugal are open now. Recruiting first, the newest first:
Eidos Therapeutics, a BridgeBio company · Sites in Portugal, United States, Argentina and 21 more countries
Ages 18–75
Leiden University Medical Center · Sites in Portugal, Belgium, Italy and 2 more countries
Ages 18+
Alnylam Pharmaceuticals · Sites in Portugal, United States, Brazil and 9 more countries
Alnylam Pharmaceuticals · Sites in Portugal, United States, France and 4 more countries
Women only
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 9
First in 2007; this study’s year is marked. 1 started in 2007.
This study's enrollment of 128 is above the median of 54 across 90 interventional studies indexed under Amyloid Neuropathies, Familial.
Median enrollment 192 across the 10 interventional studies, 300 across the 3 observational. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 13 have an industry lead sponsor. The 5 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 9 studies filed under Amyloid Neuropathies, Familial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Amyloid Neuropathies, Familial with a site in Portugal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will examine whether Fx-1006A is effective in halting the progression of Familial Amyloid Polyneuropathy (FAP).
Deposition of TTR amyloid is associated with a variety of human diseases. Deposition of amyloid fibrils of variant TTR (primarily V30M) in peripheral nerve tissue produces the condition called FAP.
The prevention of the formation of amyloid by stabilization of the TTR native state should constitute an effective therapy for amyloid diseases. Therapeutic intervention with a TTR stabilizer drug, such as Fx-1006A, is hypothesized to stop progression of the disease in FAP patients. FAP is a uniformly fatal disease and Fx-1006A is intended to halt the relentless neurological deterioration FAP patients experience.
This Phase 2/3 study will enroll early to mid-stage FAP patients in order to interrupt and stabilize the disease at a point in time where progression of motor and autonomic dysfunction can be maximally effected. Male and female patients with FAP with documented V30M TTR mutation will receive Fx-1006A or placebo once daily for a period of eighteen (18) months.
Deposition of TTR amyloid is associated with a variety of human diseases. Deposition of amyloid fibrils of variant TTR (primarily V30M) in peripheral nerve tissue produces the condition called FAP.
The prevention of the formation of amyloid by stabilization of the TTR native state should constitute an effective therapy for amyloid diseases. Therapeutic intervention with a TTR stabilizer drug, such as Fx-1006A, is hypothesized to stop progression of the disease in FAP patients. FAP is a uniformly fatal disease and Fx-1006A is intended to halt the relentless neurological deterioration FAP patients experience.
This Phase 2/3 study will enroll early to mid-stage FAP patients in order to interrupt and stabilize the disease at a point in time where progression of motor and autonomic dysfunction can be maximally effected. Male and female patients with FAP with documented V30M TTR mutation will receive Fx-1006A or placebo once daily for a period of eighteen (18) months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fx-1006A
Drug: Fx-1006A
Placebo
Drug: Placebo
Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18
Response to treatment was indicated by either improvement (decrease from baseline) or stabilization (change from baseline of 0 to less than\[\<\] 2) in NIS-LL score, based on mean of 2 scores in 1 week period. NIS-LL: assessed muscle weakness, reflexes, sensation. Each item scored separately for left, right limbs. Components of muscle weakness scored on 0(normal) to 4(paralysis) scale, higher score=greater weakness. Components of reflexes, sensation scored 0=normal, 1=decreased, or 2=absent. Total NIS-LL score range 0-88, higher score=greater impairment.
Time frame: Month 18
Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 18
Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptom was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.
Time frame: Baseline, Month 18
Change From Baseline in Neuropathy Impairment Score- Lower Limb (NIS-LL) Score at Month 6, 12 and 18
NIS-LL: assessed muscle weakness, reflexes and sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) are scored on 0(normal) to 4(paralysis) scale, higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae) and sensation (touch pressure, pin-prick, vibration, joint position) were scored 0 = normal, 1= decreased, or 2 = absent. Total possible NIS-LL score range 0-88, higher score=greater impairment.
Time frame: Baseline, Month 6, 12, 18
Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6 and 12
Response to treatment was indicated by either improvement (decrease from baseline) or stabilization (change from baseline of 0 to \<2) in NIS-LL score, based on mean of 2 scores in 1 week period. NIS-LL: assessed muscle weakness, reflexes, sensation. Each item scored separately for left, right limbs. Components of muscle weakness scored on 0 (normal) to 4 (paralysis) scale, higher score=greater weakness. Components of reflexes, sensation scored 0=normal, 1=decreased, or 2=absent. Total NIS-LL score range 0-88, higher score=greater impairment.
Time frame: Month 6, 12
Change From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 6 and 12
Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptom was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.
Time frame: Baseline, Month 6, 12
Change From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Domain Scores at Month 6, 12 and 18
Norfolk QOL-DN:35-item participant-rated questionnaire to assess impact of DN on QOL; Item 1-7:scored as 1=symptom present, 0=symptom absent. Item 8-35: scored on 5-point Likert scale: 0=no problem, 4=severe problem (except item 32: -2=much better, 0=about same, 2=much worse). Norfolk QOL-DN summarized in 5 domains(score range):physical functioning/large fiber neuropathy(-2 to 58), activities of daily living(ADLs) (0 to 20), symptoms(0 to 32), small fiber neuropathy(0 to 16), autonomic neuropathy(0 to 12); higher score=greater impairment, for each. Total score=-2 to138(higher score=worse QOL).
Time frame: Baseline, Month 6, 12, 18
Change From Baseline in Summated 7 Score for Large Nerve Fiber Function at Month 6, 12 and 18
Summated 7 score: composite score included five Nerve Conduction Studies (NCS) attributes (peroneal nerve distal motor latency, peroneal nerve compound muscle action potential, peroneal nerve motor conduction velocity, tibial nerve distal motor latency, and sural nerve sensory nerve action potential amplitude) along with Vibration Detection Threshold (VDT) obtained in great toes, and Heart Rate Response to Deep Breathing (HRDB) value. Score was determined through reference to normal values for age, sex and height. Total score range= -26 to 26, where higher score=worse nerve function.
Time frame: Baseline, Month 6, 12, 18
Change From Baseline in Summated 3 Score for Small Nerve Fiber Function at Month 6, 12 and 18
Summated 3 Nerve Tests Small Fiber Normal Deviates Score (NTSFnds) included cooling threshold for the lower limbs, heat pain threshold for the lower limbs and HRDB. Total score range= -11.2 to 11.2, where higher score=worse nerve function.
Time frame: Baseline, Month 6, 12, 18
Change From Baseline in Modified Body Mass Index (mBMI) at Month 6, 12 and 18
BMI was calculated by weight divided by height squared. mBMI was calculated by multiplying BMI by serum albumin levels to compensate for edema formation associated with malnutrition. A progressive decline in mBMI indicated worsening of disease severity.
Time frame: Baseline, Month 6, 12, 18
Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer
TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.
Time frame: Week 8, Month 6, 12, 18
| Milestone | Tafamidis | Placebo |
|---|---|---|
| Started | 65 | 63 |
| Completed | 47 | 44 |
| Not completed | 18 | 19 |
| Withdrew: Adverse event | 4 | 3 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Negative genotype | 0 | 1 |
| Withdrew: Liver transplantation | 13 | 13 |
Response to treatment was indicated by either improvement (decrease from baseline) or stabilization (change from baseline of 0 to less than\[\<\] 2) in NIS-LL score, based on mean of 2 scores in 1 week period. NIS-LL: assessed muscle weakness, reflexes, sensation. Each item scored separately for left, right limbs. Components of muscle weakness scored on 0(normal) to 4(paralysis) scale, higher score=greater weakness. Components of reflexes, sensation scored 0=normal, 1=decreased, or 2=absent. Total NIS-LL score range 0-88, higher score=greater impairment.
| percentage of participants | Tafamidis | Placebo |
|---|---|---|
| Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18 | 45.3 (33.1 to 57.5) | 29.5 (18.1 to 41.0) |
Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptom was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.
| units on a scale | Tafamidis | Placebo |
|---|---|---|
| Baseline | 27.3 ± 24.2 | 30.8 ± 26.7 |
| Change at Month 18 | 2.4 ± 14.6 | 6.9 ± 22.9 |
NIS-LL: assessed muscle weakness, reflexes and sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) are scored on 0(normal) to 4(paralysis) scale, higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae) and sensation (touch pressure, pin-prick, vibration, joint position) were scored 0 = normal, 1= decreased, or 2 = absent. Total possible NIS-LL score range 0-88, higher score=greater impairment.
| units on a scale | Tafamidis | Placebo |
|---|---|---|
| Baseline (n=64, 61) | 8.359 ± 11.399 | 11.445 ± 13.544 |
| Change at Month 6 (n=60, 57) | 1.260 ± 3.007 | 2.075 ± 6.407 |
| Change at Month 12 (n=49, 50) | 1.005 ± 3.964 | 4.835 ± 7.697 |
| Change at Month 18 (n=48, 47) | 2.193 ± 4.372 | 5.402 ± 8.661 |
Response to treatment was indicated by either improvement (decrease from baseline) or stabilization (change from baseline of 0 to \<2) in NIS-LL score, based on mean of 2 scores in 1 week period. NIS-LL: assessed muscle weakness, reflexes, sensation. Each item scored separately for left, right limbs. Components of muscle weakness scored on 0 (normal) to 4 (paralysis) scale, higher score=greater weakness. Components of reflexes, sensation scored 0=normal, 1=decreased, or 2=absent. Total NIS-LL score range 0-88, higher score=greater impairment.
| percentage of participants | Tafamidis | Placebo |
|---|---|---|
| Month 6 | 60.9 (49.0 to 72.9) | 54.1 (41.6 to 66.6) |
| Month 12 | 54.7 (42.5 to 66.9) | 32.8 (21.0 to 44.6) |
Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptom was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.
| units on a scale | Tafamidis | Placebo |
|---|---|---|
| Baseline (n=64, 61) | 27.3 ± 24.2 | 30.8 ± 26.7 |
| Change at Month 6 (n=60, 57) | 1.2 ± 15.6 | 0.2 ± 15.1 |
| Change at Month 12 (n=49, 50) | 1.1 ± 14.7 | 4.6 ± 19.0 |
Norfolk QOL-DN:35-item participant-rated questionnaire to assess impact of DN on QOL; Item 1-7:scored as 1=symptom present, 0=symptom absent. Item 8-35: scored on 5-point Likert scale: 0=no problem, 4=severe problem (except item 32: -2=much better, 0=about same, 2=much worse). Norfolk QOL-DN summarized in 5 domains(score range):physical functioning/large fiber neuropathy(-2 to 58), activities of daily living(ADLs) (0 to 20), symptoms(0 to 32), small fiber neuropathy(0 to 16), autonomic neuropathy(0 to 12); higher score=greater impairment, for each. Total score=-2 to138(higher score=worse QOL).
| units on a scale | Tafamidis | Placebo |
|---|---|---|
| Baseline: physical functioning(n=64,61) | 14.3 ± 13.8 | 16.6 ± 14.7 |
| Baseline: ADLs(n=64,61) | 1.3 ± 2.9 | 1.6 ± 3.8 |
| Baseline: symptoms(n=64,61) | 7.2 ± 5.5 | 7.6 ± 6.1 |
| Baseline: small fiber neuropathy(n=64,61) | 2.7 ± 3.6 | 3.1 ± 4.0 |
| Baseline: autonomic neuropathy(n=64,61) | 1.9 ± 2.4 | 2.0 ± 2.6 |
| Change at Month 6: physical functioning(n=60,57) | -0.6 ± 8.0 | -0.9 ± 9.8 |
| Change at Month 6: ADLs(n=60,57) | 0.4 ± 1.9 | 0.3 ± 1.7 |
| Change at Month 6: symptoms(n=60,56) | 0.8 ± 5.5 | 0.2 ± 4.4 |
| Change at Month 6: small fiber neuropathy(n=60,57) | 0.4 ± 2.2 | 0.5 ± 2.5 |
| Change at Month 6: autonomic neuropathy(n=60,57) | 0.2 ± 1.8 | 0.0 ± 1.7 |
| Change at Month 12: physical functioning(n=49,50) | -0.9 ± 7.4 | 0.6 ± 10.7 |
| Change at Month 12: ADLs(n=49,50) | 1.0 ± 2.4 | 0.7 ± 3.0 |
| Change at Month 12: symptoms(n=49,49) | 0.4 ± 5.0 | 1.4 ± 4.5 |
| Change at Month 12:small fiber neuropathy(n=49,50) | 0.7 ± 2.8 | 1.5 ± 3.1 |
| Change at Month 12: autonomic neuropathy(n=49,50) | -0.1 ± 1.8 | 0.4 ± 2.8 |
| Change at Month 18: physical functioning(n=48,47) | -0.1 ± 8.5 | 3.0 ± 14.0 |
| Change at Month 18: ADLs(n=48,47) | 1.2 ± 2.4 | 1.2 ± 4.2 |
| Change at Month 18: symptoms(n=48,47) | -0.1 ± 4.9 | 1.2 ± 5.4 |
| Change at Month 18:small fiber neuropathy(n=48,47) | 0.8 ± 2.6 | 1.4 ± 3.6 |
| Change at Month 18: autonomic neuropathy(n=48,47) | 0.2 ± 1.9 | 0.4 ± 2.8 |
Summated 7 score: composite score included five Nerve Conduction Studies (NCS) attributes (peroneal nerve distal motor latency, peroneal nerve compound muscle action potential, peroneal nerve motor conduction velocity, tibial nerve distal motor latency, and sural nerve sensory nerve action potential amplitude) along with Vibration Detection Threshold (VDT) obtained in great toes, and Heart Rate Response to Deep Breathing (HRDB) value. Score was determined through reference to normal values for age, sex and height. Total score range= -26 to 26, where higher score=worse nerve function.
| units on a scale | Tafamidis | Placebo |
|---|---|---|
| Baseline (n=64, 61) | 7.787 ± 9.063 | 8.718 ± 8.533 |
| Change at Month 6 (n=60, 57) | 0.581 ± 3.542 | 1.934 ± 3.846 |
| Change at Month 12 (n=48, 50) | 0.833 ± 3.963 | 2.959 ± 3.879 |
| Change at Month 18 (n=48, 46) | 1.159 ± 3.853 | 3.333 ± 4.997 |
Summated 3 Nerve Tests Small Fiber Normal Deviates Score (NTSFnds) included cooling threshold for the lower limbs, heat pain threshold for the lower limbs and HRDB. Total score range= -11.2 to 11.2, where higher score=worse nerve function.
| units on a scale | Tafamidis | Placebo |
|---|---|---|
| Baseline (n=64, 61) | 5.514 ± 4.535 | 5.624 ± 4.085 |
| Change at Month 6 (n=60, 57) | 0.240 ± 1.679 | 0.716 ± 2.202 |
| Change at Month 12 (n=48, 50) | 0.375 ± 2.048 | 1.250 ± 2.010 |
| Change at Month 18 (n=48, 46) | 0.290 ± 2.130 | 1.489 ± 2.519 |
BMI was calculated by weight divided by height squared. mBMI was calculated by multiplying BMI by serum albumin levels to compensate for edema formation associated with malnutrition. A progressive decline in mBMI indicated worsening of disease severity.
| (kilogram/square meter)*(gram/liter) | Tafamidis | Placebo |
|---|---|---|
| Baseline (n=64, 61) | 1004.6 ± 165.2 | 1011.5 ± 212.9 |
| Change at Month 6 (n=60, 56) | 17.1 ± 68.4 | -29.8 ± 69.7 |
| Change at Month 12 (n=49, 50) | 19.4 ± 71.8 | -30.8 ± 74.9 |
| Change at Month 18 (n=49, 46) | 37.9 ± 73.7 | -32.7 ± 88.6 |
TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.
| percentage of participants | Tafamidis | Placebo |
|---|---|---|
| Week 8 (n=63, 60) | 98.4 (95.3 to 100.0) | 6.7 (0.4 to 13.0) |
| Month 6 (n= 59, 58) | 100.0 (100.0 to 100.0) | 5.2 (0.0 to 10.9) |
| Month 12 (n=48, 50) | 97.9 (93.9 to 100.0) | 2.0 (0.0 to 5.9) |
| Month 18 (n=48, 44) | 97.9 (93.9 to 100.0) | 0.0 (0.0 to 0.0) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tafamidis | — | 6/65 (9.2%) | 57/65 (87.7%) |
| Placebo | — | 5/63 (7.9%) | 56/63 (88.9%) |
| Event | Tafamidis | Placebo |
|---|---|---|
| Urinary tract infectionInfections and infestations | 2/65 | 0/63 |
| AnaemiaBlood and lymphatic system disorders | 0/65 | 1/63 |
| Cardiac amyloidosisCardiac disorders | 0/65 | 1/63 |
| NauseaGastrointestinal disorders | 0/65 | 1/63 |
| VomitingGastrointestinal disorders | 0/65 | 1/63 |
| Catheter site phlebitisGeneral disorders | 0/65 | 1/63 |
| Oedema peripheralGeneral disorders | 0/65 | 1/63 |
| CellulitisInfections and infestations | 0/65 | 1/63 |
| LymphangitisInfections and infestations | 0/65 | 1/63 |
| Staphylococcal infectionInfections and infestations | 0/65 | 1/63 |
| Event | Tafamidis | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 17/65 | 11/63 |
| Urinary tract infectionInfections and infestations | 14/65 | 8/63 |
| HeadacheNervous system disorders | 10/65 | 12/63 |
| NeuralgiaNervous system disorders | 2/65 | 12/63 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 11/65 | 6/63 |
| ParaesthesiaNervous system disorders | 3/65 | 10/63 |
| InfluenzaInfections and infestations | 10/65 | 9/63 |
| NasopharyngitisInfections and infestations | 9/65 | 8/63 |
| NauseaGastrointestinal disorders | 8/65 | 8/63 |
| Oedema peripheralGeneral disorders | 4/65 | 8/63 |
| Age, Customized(participants) | Tafamidis | Placebo | Total |
|---|---|---|---|
| Less than or equal to 65 years | 59 | 58 | 117 |
| Greater than 65 years | 5 | 3 | 8 |
| Sex: Female, Male(Participants) | Tafamidis | Placebo | Total |
|---|---|---|---|
| Female | 32 | 35 | 67 |
| Male | 32 | 26 | 58 |
The record gives a start of Jan 2007, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 3 years 7 months after primary completion. A results delay was requested in Mar 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tafamidis
Amyloid Neuropathies, Familial →